Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.

ABSTRACT: Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation. This study aimed to characterise patients who received mepolizumab in the nATU. This retrospective, observational study analysed data from the hospital medical records of patients up to 24 months after treatment initiation. Study objectives were to describe patient baseline characteristics, the evolution of disease severity and treatment modifications during follow-up; safety was also investigated. Overall, 146 patients who received ≥1 dose of mepolizumab were included. At inclusion, patients had a mean age of 58.2 years with a mean severe asthma duration of

SUBMITTER: Taille C 

PROVIDER: S-EPMC7315004 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature